Trial Profile
A phase II trial to evaluate a neuroblastoma vaccine in patients with childhood neuroblastoma.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2019
Price :
$35
*
At a glance
- Drugs Neuroblastoma vaccine (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- 12 Dec 2019 According to a MabVax media release, te company plan to start this trial in 2020.
- 01 Dec 2015 Planned initiation date changed from 1 Jan 2015 to 1 Jan 2016, as per MabVax media release.
- 04 Feb 2015 According to MabVax media release, company received an Orphan Drug Designation from FDA in Sept 2014.